Elixiron Immunotherapeutics

company

About

Elixiron Immunotherapeutics is a company developing therapeutics for cancer, rare, and inflammatory disorders

  • 11 - 50

Details

Last Funding Type
Series A
Industries
Biotechnology
Founded date
Jan 1, 2017
Number Of Employee
11 - 50
Operating Status
Active

Elixiron Immunotherapeutics is driven by an international team with a shared vision to produce next-generation immunotherapies. This vision drives our mission to target rare and inflammatory disorders as well as cancer for indications that could substantially benefit from advances in immunotherapy approaches. We employ advances in translational medicine to identify targets from clinical observations, and various drug modalities including biologics derived from a proprietary human antibody domain phage display library and a single human B cell antibody cloning platform to develop innovative therapies. Our two lead pipeline candidates are in phase 1 clinical trials. EI-1071, a small molecule inhibitor of CSF-1R kinase activity, is being explored as a potential therapy for Alzheimer's disease as well as tenosynovial giant cell tumors, and a monoclonal antibody, EI-001 is being developed for the treatment of vitiligo and other immunological disorders.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
Elixiron Immunotherapeutics has raised a total of — in funding over 2 rounds. Their latest funding was raised on Aug 23, 2021 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 23, 2021 Series A 1 Pangu Venture Capital Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Elixiron Immunotherapeutics is funded by 1 investors. Pangu Venture Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Pangu Venture Capital Yes Series A